当前位置： SCI文献检索 > Clinical Breast Cancer期刊下所有文献 > Evaluation of Multifocality and Multicentricity With Breast Magnetic Resonance Imaging in Each Breast Cancer Subtype.

Evaluation of Multifocality and Multicentricity With Breast Magnetic Resonance Imaging in Each Breast Cancer Subtype.

Abstract：

INTRODUCTION:The purpose of this study was to evaluate whether diagnostic performance of breast magnetic resonance imaging (MRI) for detection of multifocality and multicentricity (MFMC) of breast cancer (BC) can be influenced by different histotypes or immunophenotypes in newly diagnosed patients with breast cancer. MATERIALS AND METHODS:In this institutional review board-approved retrospective study, 289 patients who underwent both preoperative breast MRI and radical or modified mastectomy in our institution because of primary BCs were selected. Patients were stratified based on the pathologic report in 2 main histotypes and 5 immunophenotypes. By matching the radiologic report with the corresponding pathologic report for each patient, breast MRI performance for detection of MFMC were obtained in each histotype and immunophenotype and subsequently compared. RESULTS:Overall breast MRI sensitivity for MFMC detection was 88.1%, specificity was 80.0%, positive predictive value 82.1%, negative predictive value 85.8%, diagnostic accuracy 83.7%, and area under the curve 0.835. Breast MRI sensitivity for MFMC detection in triple-negative BC was 84.6% (P = .88), specificity 70.8% (P = .63), positive predictive value 61.1% (P = .02), negative predictive value 89.5% (P = .20), diagnostic accuracy 75.7% (P = .65), and area under the curve 0.777 (P = .87). CONCLUSION:Performance of breast MRI for the detection of MFMC are not influenced by the BC histotypes, in accordance with published literature. Conversely, the triple-negative immunophenotypes demonstrated lower performance, statistically significant only for positive predictive value (P = .02), for the detection of MFMC.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Prochowski Iamurri A,Ponziani M,Macchini M,Fogante M,Pistelli M,De Lisa M,Berardi R,Giuseppetti GM

doi

10.1016/j.clbc.2017.10.012

subject

Has Abstract

pub_date

2018-04-01 00:00:00

pages

e231-e235

issue

2

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(17)30164-7

journal_volume

18

pub_type

杂志文章

相关文献

Clinical Breast Cancer文献大全
  • Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients.

    abstract：BACKGROUND:Intensive chemotherapy confers benefit to patients with high-risk early breast cancer (BC). We characterized the feasibility and toxicity profile of anthracycline-containing adjuvant chemotherapy (ACAC) in older women with early BC. PATIENTS AND METHODS:Available data from women who received ACAC for BC in ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2015.12.001

    authors： Karavasilis V,Papadimitriou C,Gogas H,Kouvatseas G,Pentheroudakis G,Koutras A,Christodoulou C,Bafaloukos D,Samantas E,Pisanidis N,Papakostas P,Aravantinos G,Karanikiotis C,Kosmidis P,Pectasides D,Dimopoulos MA,Fountzilas

    更新日期：2016-08-01 00:00:00

  • Nipple-sparing Mastectomy for the Management of Recurrent Breast Cancer.

    abstract：INTRODUCTION:For patients who have an ipsilateral breast cancer recurrence following prior breast-conserving surgery and radiation, total mastectomy generally is recommended. However, little is known about the suitability and outcomes of nipple-sparing mastectomy (NSM) with immediate breast reconstruction for the treat...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.10.011

    authors： Murphy BL,Boughey JC,Hieken TJ

    更新日期：2017-07-01 00:00:00

  • Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.

    abstract：:Breast cancer is the most common type of cancer among women and the second leading cause of cancer death in the United States. Metastatic breast cancer is considered incurable, and treatment is aimed at palliating symptoms, achieving remission, and prolonging survival. Treatment options for metastatic disease vary bas...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2011.07.001

    authors： Sachdev JC,Jahanzeb M

    更新日期：2012-02-01 00:00:00

  • N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane-Containing Therapy.

    abstract：BACKGROUND:Irinotecan has a 20% to 25% response rate (RR) in patients with previously treated metastatic breast cancer (MBC). Epidermal growth factor receptor (EGFR) is overexpressed in some MBC, especially in triple-negative breast cancer (TNBC). Cetuximab is a monoclonal antibody against EGFR with additive preclinica...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2015.08.002

    authors： Crozier JA,Advani PP,LaPlant B,Hobday T,Jaslowski AJ,Moreno-Aspitia A,Perez EA

    更新日期：2016-02-01 00:00:00

  • Detection of breast cancer in an FDG-PET cancer screening program: results of a nationwide Japanese survey.

    abstract：BACKGROUND:The [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program is defined as cancer screening for asymptomatic subjects using FDG-PET/computed tomography with or without combination of other screening tests. The aim of this study was to analyze the detection rate and effectivene...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2014.09.008

    authors： Minamimoto R,Senda M,Jinnouchi S,Terauchi T,Yoshida T,Inoue T

    更新日期：2015-04-01 00:00:00

  • Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients.

    abstract：BACKGROUND:Nanosomal docetaxel lipid suspension formulation was developed to eliminate ethanol and polysorbate 80 from the currently used docetaxel (Taxotere) drug for treatment of cancer patients. NDLS clinical safety and efficacy was evaluated and compared with Taxotere at 75 mg/m(2) in metastatic breast cancer patie...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clbc.2013.09.011

    authors： Ahmad A,Sheikh S,Taran R,Srivastav SP,Prasad K,Rajappa SJ,Kumar V,Gopichand M,Paithankar M,Sharma M,Rane RC,Ahmad I

    更新日期：2014-06-01 00:00:00

  • Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology.

    abstract：BACKGROUND:Brain metastasis (BM) is a life-threatening event in breast cancer patients. Identifying patients at a high risk for BM can help to adopt screening programs and test preventive interventions. We tried to identify the incidence of BM in different stages and subtypes of breast cancer. PATIENTS AND METHODS:We ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.08.004

    authors： Azim HA,Abdel-Malek R,Kassem L

    更新日期：2018-04-01 00:00:00

  • Prevalence of Ectopic Breast Tissue and Tumor: A 20-Year Single Center Experience.

    abstract：BACKGROUND:Ectopic breast tissue, which includes both supernumerary breast and aberrant breast tissue, is the most common congenital breast abnormality. Ectopic breast cancers are rare neoplasms that occur in 0.3% to 0.6% of all cases of breast cancer. PATIENTS AND METHODS:We retrospectively report, using a large seri...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.03.004

    authors： Famá F,Cicciú M,Sindoni A,Scarfó P,Pollicino A,Giacobbe G,Buccheri G,Taranto F,Palella J,Gioffré-Florio M

    更新日期：2016-08-01 00:00:00

  • Rheumatic disorders and functional disability with aromatase inhibitor therapy.

    abstract：BACKGROUND:Aromatase inhibitor therapy is often effective for breast cancer, yet it can be accompanied by musculoskeletal pain and stiffness. This prevalence assessment aimed to characterize a rheumatologist's view of frequency and clinical features, including associated disability, within a breast cancer clinic panel ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.3816/CBC.2010.n.019

    authors： Moxley G

    更新日期：2010-04-01 00:00:00

  • Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).

    abstract：:In addition to classical clinicopathologic factors, such as hormone receptor positivity, human epidermal growth factor receptor 2 (HER2) status, and tumor size, grade, and lymph node status, a number of commercially available genomic tests may be used to help inform treatment decisions for early breast cancer patients...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2020.01.001

    authors： Kittaneh M,Badve S,Caldera H,Coleman R,Goetz MP,Mahtani R,Mamounas E,Kalinsky K,Lower E,Pegram M,Press MF,Rugo HS,Schwartzberg L,Traina T,Vogel C

    更新日期：2020-06-01 00:00:00

  • Disease-free survival according to the use of postmastectomy radiation therapy after neoadjuvant chemotherapy.

    abstract：INTRODUCTION:The purpose of the study was to determine predictors of recurrence for patients treated with neoadjuvant chemotherapy (NAC) and mastectomy according to the use of postmastectomy radiation therapy (PMRT). PATIENTS AND METHODS:An analysis of 161 clinically staged T1 to T3/N0 to N3 patients treated with NAC ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2014.09.012

    authors： Nagar H,Boothe D,Ginter PS,Sison C,Vahdat L,Shin S,Smith M,Chao KS,Nori D,Hayes MK

    更新日期：2015-04-01 00:00:00

  • Five-Year Oncologic Outcomes of Volume Displacement Procedures After Partial Mastectomy for Breast Cancer.

    abstract：BACKGROUND:Volume displacement techniques that use remnant breast tissue are useful in reconstructive procedures after partial mastectomy. The authors analyzed the oncologic results of volume displacement surgery after partial mastectomy and their associations with various clinicopathologic factors. PATIENTS AND METHO...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.06.018

    authors： Lee J,Jung JH,Kim WW,Hwang SO,Chae YS,Lee SJ,Yang JD,Lee JW,Park HY

    更新日期：2017-02-01 00:00:00

  • Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

    abstract：BACKGROUND:Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated liposomal doxorubicin (PLD), which both showed activity in breast cancer, we conducted a phase II study of this regimen in patients with metastatic breast cancer. PATIENTS AND METHODS:Patients received bortezomib...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.3816/CBC.2010.n.061

    authors： Irvin WJ Jr,Orlowski RZ,Chiu WK,Carey LA,Collichio FA,Bernard PS,Stijleman IJ,Perou C,Ivanova A,Dees EC

    更新日期：2010-12-01 00:00:00

  • Transcription Factor EB Expression in Early Breast Cancer Relates to Lysosomal/Autophagosomal Markers and Prognosis.

    abstract：BACKGROUND:Disrupting the autophagic balance to trigger autophagic death may open new strategies for cancer therapy. Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and may play a role in cancer biology and clinical behavior. METHODS:The expression of TFEB and the lysosomal cancer cell con...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.11.006

    authors： Giatromanolaki A,Sivridis E,Kalamida D,Koukourakis MI

    更新日期：2017-06-01 00:00:00

  • Nomogram for Predicting the Overall Survival of Patients With Breast Cancer With Pathologic Nodal Status N3.

    abstract：BACKGROUND:Patients with breast cancer with pathologic N3 (pN3) lymph node status have been proven to have a poor prognosis. This study aimed to establish a nomogram to predict overall survival (OS) in patients with pN3 breast cancer. MATERIALS AND METHODS:The eligible patients from the Surveillance, Epidemiology, and...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.06.002

    authors： Wang J,Chen L,Nie Y,Wu W,Yao Y

    更新日期：2020-12-01 00:00:00

  • The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer.

    abstract：BACKGROUND:There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2+ breast cancer (BC). The aim of this study was to assess the impact of local and systemic treatments on the outcome of patients diagnosed with BM from HER2+ BC over a period of 10 years, from 200...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clbc.2019.05.006

    authors： Gori S,Puglisi F,Moroso S,Fabi A,La Verde N,Frassoldati A,Tarenzi E,Garrone O,Vici P,Laudadio L,Cretella E,Turazza M,Foglietta J,Leonardi V,Cavanna L,Barni S,Galanti D,Russo A,Marchetti F,Valerio M,Lunardi G,Alo

    更新日期：2019-08-01 00:00:00

  • Dietary Patterns and Risk of Invasive Ductal and Lobular Breast Carcinomas: A Systematic Review and Meta-analysis.

    abstract：:The histopathologic subtypes of breast cancer, including invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), differ in terms of risk factors, progression, and response to treatment. The PubMed/Medline, Web of Science, and Scopus databases were searched up to February 2020 for published studies on the...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2020.03.007

    authors： Dianatinasab M,Rezaian M,HaghighatNezad E,Bagheri-Hosseinabadi Z,Amanat S,Rezaeian S,Masoudi A,Ghiasvand R

    更新日期：2020-08-01 00:00:00

  • Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the hellenic cooperative oncology group.

    abstract：:Despite the widespread use of trastuzumab in the management of patients with HER2-overexpressing metastatic breast cancer, its optimal duration of administration is unknown. We retrospectively reviewed the medical records of 80 such patients who received trastuzumab monotherapy or combination chemotherapy beyond disea...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/cbc.2003.n.017

    authors： Fountzilas G,Razis E,Tsavdaridis D,Karina M,Labropoulos S,Christodoulou C,Mavroudis D,Gogas H,Georgoulias V,Skarlos D

    更新日期：2003-06-01 00:00:00

  • Clinical Impact of 21-Gene Recurrence Score Test Within the Veterans Health Administration: Utilization and Receipt of Guideline-Concordant Care.

    abstract：INTRODUCTION:Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gene Recurrence Score test, which predicts 10-year risk of breast ca...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.11.018

    authors： Hull LE,Lynch JA,Berse BB,DuVall SL,Chun DS,Venne VL,Efimova OV,Icardi MS,Kelley MJ

    更新日期：2018-04-01 00:00:00

  • Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer.

    abstract：PURPOSE:The 8th edition of the American Joint Committee on Cancer (AJCC) breast cancer staging system requires histologic grade (GR), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and stage (assessed by the tumor, node, metastasis classification system). For T1-2 N...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2018.10.005

    authors： Breaux A,Turner B,Wu X,Rai SN,Riley EC,Mandadi M,Sanders MA

    更新日期：2019-02-01 00:00:00

  • Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study.

    abstract：BACKGROUND:Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI) and previous use of taxanes in the neoadjuvant or adjuvant setting have been associated with worse outcomes for patients receiving first-line chemother...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clbc.2018.12.012

    authors： Ortega V,Antón A,Garau I,Afonso N,Calvo L,Fernández Y,Martínez-García M,Blanco E,Zamora P,García M,Illarramendi JJ,Rodríguez Sánchez CA,Sampayo M,Aguirre E,Pérez-García JM,Cortés J,Llombart-Cussac A

    更新日期：2019-04-01 00:00:00

  • Role of Overweight, Obesity, and Comorbidities in the Prognosis of Patients With Breast Cancer With Brain Metastases.

    abstract：INTRODUCTION:Breast cancer (BC) is the most common cancer in women, and the incidence of brain metastasis (BM) from BC ranges from 20% to 30%, with a median survival of 10 to 15 months. Previous reports have shown that the presence of obesity or diabetes negatively impacts survival. The present study investigates the a...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clbc.2018.12.018

    authors： Cacho-Díaz B,Spínola-Maroño H,Reynoso N,González-Aguilar A,Mohar-Betancourt A

    更新日期：2019-04-01 00:00:00

  • Intravenous or oral vinorelbine plus capecitabine as first-line treatment in HER2- metastatic breast cancer: joint analysis of 2 consecutive prospective phase II trials.

    abstract：BACKGROUND:The purpose of this study was to assess the activity and safety of the combination of vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-negative (HER(-)) metastatic breast cancer (MBC). PATIENTS AND METHODS:Patients (42) enrolled in trial A received intravenous (i.v.) VNR 25 mg/m2 on ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2011.11.001

    authors： Strada MR,Palumbo R,Bernardo A,Riccardi A,Teragni C,Poggi G,Frascaroli M,Amatu A,Montagna B,Sottotetti F,Tagliaferri B,Bernardo G

    更新日期：2012-02-01 00:00:00

  • Prevalence and prognostic role of triple-negative breast cancer by race: a surveillance study.

    abstract：INTRODUCTION:Emerging research suggests a substantially greater prevalence of the adverse triple-negative (TN) subtype (human epidermal growth factor receptor [HER]2(-), estrogen receptor [ER](-), and progesterone receptor [PR])(-)) among black patients with breast cancer. No reports however have been generated from a ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2011.04.004

    authors： Swede H,Gregorio DI,Tannenbaum SH,Brockmeyer JA,Ambrosone C,Wilson LL,Pensa MA,Gonsalves L,Stevens RG,Runowicz CD

    更新日期：2011-10-01 00:00:00

  • Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.

    abstract：BACKGROUND:Although brain metastases (BM) are associated with poor prognosis, patients with human epidermal growth factor receptor 2 (HER2) overexpressing (HER2+) breast cancer (BC) with BM who are treated with anti-HER2 therapy have a relatively longer survival after BM diagnosis compared with other subtypes and HER2+...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.12.009

    authors： Morikawa A,Wang R,Patil S,Diab A,Yang J,Hudis CA,McArthur HL,Beal K,Seidman AD

    更新日期：2018-10-01 00:00:00

  • Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study.

    abstract：INTRODUCTION:Dose-dense therapies have had a major effect on reducing toxicity and improving outcomes in breast cancer. A combination of TC every 3 weeks has emerged as a common chemotherapy regimen used for treatment of node-negative or lower-risk node-positive breast cancer. We tested whether it is feasible to delive...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2013.10.018

    authors： Burkard ME,Wisinski KB,Njiaju UO,Donohue S,Hegeman R,Stella A,Mansky P,Shah V,Goggins T,Qamar R,Dietrich L,Kim K,Traynor AM,Tevaarwerk AJ

    更新日期：2014-06-01 00:00:00

  • Physical Exercise Positively Influences Breast Cancer Evolution.

    abstract：:Breast cancer is one of the most commonly diagnosed types of cancer in women. Its pathogenesis involves genetic, hormonal, and environmental factors. A large body of evidence indicates that physical activity has positive effects on every aspect of breast cancer evolution, including prevention, medical treatment, and a...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2017.05.003

    authors： Adraskela K,Veisaki E,Koutsilieris M,Philippou A

    更新日期：2017-10-01 00:00:00

  • The evolving role of aromatase inhibitors in adjuvant breast cancer therapy.

    abstract：:The development of third-generation aromatase inhibitors (AIs) has brought about a major change in the therapeutic approach to patients with hormone-sensitive breast cancer. In randomized clinical trials, each of the third-generation AIs has demonstrated efficacy in the adjuvant treatment of postmenopausal women with ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2005.n.022

    authors： Henderson IC,Piccart-Gebhart MJ

    更新日期：2005-08-01 00:00:00

  • An independent assessment of the 7 nomograms for predicting the probability of additional axillary nodal metastases after positive sentinel lymph node biopsy in a cohort of British patients with breast cancer.

    abstract：INTRODUCTION:Axillary lymph node dissection (ALND) is currently the recommended procedure in patients with tumor-positive sentinel lymph node biopsy (SLNB). A significant proportion of patients with positive SLNs will not have any additional metastases in nonsentinel lymph nodes (NSLNs). Predictive nomograms could iden...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2014.02.006

    authors： Nadeem RM,Gudur LD,Saidan ZA

    更新日期：2014-08-01 00:00:00

  • Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic.

    abstract：BACKGROUND:Single-frequency bioelectrical impedance (BI) has been used to measure extracellular fluid in the upper limbs. The purpose of the study was to evaluate BI's ability to detect and monitor upper limb changes in based upon the extent of various treatments and to assess its practicality. METHODS:Patients with n...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2012.01.004

    authors： Vicini F,Shah C,Lyden M,Whitworth P

    更新日期：2012-04-01 00:00:00